HER2基因蛋白分析：一种可用于评估子宫内膜癌中HER2状态和肿瘤内异质性的强大工具
HER2 Gene Protein Assay: A Robust Tool for Evaluating HER2 Status and Intratumoral Heterogeneity in Endometrial Cancers
影响因子:1.90000
分区:医学4区 / 病理学3区
发表日期:2023 May 02
作者:
Saba Shafi, Hiroaki Nitta, Manan Shah, Bindu Challa, Anil V Parwani, Zaibo Li
摘要
子宫内膜癌中的人表皮生长因子受体2（HER2）状态通常由免疫组织化学和/或原位杂交确定。我们采用了一种新型的HER2基因蛋白测定（GPA），同时评估HER2基因扩增和蛋白质表达在高级子宫内膜癌中。我们在180个子宫内膜癌中进行了GPA，包括106个浆液性癌，包括106个浆液性癌，34个Carcinosarcomas，34个癌和40个混合混合上皮carcinalial carcinomas。 HER2状态是使用2018年HER2乳腺癌指南确定的，并检查了HER2肿瘤内异质性（ITH）。收集了临床病理特征并与HER2状态相关。在32％的浆液性癌中发现了HER2阳性，显着高于癌肉瘤（5.9％）和混合癌（12.5％）。在32％的浆液癌中检测到HER2 ITH，明显大于癌（8.8％）和混合癌（10％）。癌肉瘤患者的总生存率明显低于浆液性或混合上皮癌患者，但HER2状态在浆液性癌患者中没有差异。HER2GPA可用于确定心形癌症中的HER2状态，并且是确定HER2 HER2异质态的高度价值工具。
Abstract
Human epidermal growth factor receptor 2 (HER2) status in endometrial cancer is usually determined by immunohistochemistry and/or in situ hybridization. We employed a novel HER2 gene protein assay (GPA) to simultaneously assesses HER2 gene amplification and protein expression in high-grade endometrial cancers.We performed GPA in 180 endometrial cancers, including 106 serous carcinomas, 34 carcinosarcomas, and 40 mixed epithelial carcinomas. HER2 status was determined using the 2018 HER2 guidelines for breast carcinoma, and HER2 intratumoral heterogeneity (ITH) was examined. Clinicopathologic characteristics were collected and correlated with HER2 status.HER2 positivity was noted in 32% of serous carcinomas, significantly higher than in carcinosarcomas (5.9%) and mixed carcinomas (12.5%). HER2 ITH was detected in 32% of serous carcinomas, significantly greater than in carcinosarcomas (8.8%) and mixed carcinomas (10%). Patients with carcinosarcoma had a significantly lower overall survival than patients with serous or mixed epithelial carcinoma, but HER2 status caused no difference in survival in patients with serous carcinoma.HER2 GPA can be used to accurately determine HER2 status in endometrial cancers and is a highly valuable tool for identifying HER2 heterogeneity.